Results 211 to 220 of about 650,104 (308)

Bipolar androgen therapy as platform for personalized medicine in castration-resistant prostate cancer. [PDF]

Discov Oncol
Lilleby W, Geinitz H, Denmeade S.
europepmc   +1 more source

Restoration of Immune Surveillance in Prostate Cancer Prevention by Sulforaphane in Hi‐Myc Mice

Molecular Carcinogenesis, Volume 65, Issue 6, Page 677-686, June 2026.
ABSTRACT Oral administration of broccoli constituent sulforaphane (SFN) prevents prostate cancer development in preclinical mouse models. However, the mechanism(s) underlying prostate cancer prevention by SFN are not fully understood. In this study, we used a human relevant mouse model (Hi‐Myc mice) to demonstrate restoration of immune surveillance by ...
Krishna B. Singh, Eun‐Ryeong Hahm, Joshi J. Alumkal, Shivendra V. Singh   +3 more
wiley   +1 more source

GNL3 Orchestrates AR Transcriptional Programs to Drive Castration-Resistant Prostate Cancer and Immune Evasion. [PDF]

Adv Sci (Weinh)
Zhang C, Cheong TL, Narwade N, Dong D, Deng M, Miao Z, Ding Z, Li W, Lei KMK, Wei GH, Poon TCW, Deng CX, Cheung E.   +12 more
europepmc   +1 more source

Fatty Acid Metabolism in Health and Cancer: From Fundamental Mechanisms to Therapeutic Application

MedComm, Volume 7, Issue 6, June 2026.
The modulation of the TME by fatty acid metabolism primarily occurs through four key pathways: inflammation regulation, signal transduction, translation to TME, and oxidative stress. ABSTRACT Fatty acid metabolism (FAM) plays a vital role in maintaining health by supporting energy production, cellular structure, and signaling processes.
Na Hang, Runkang Zhao, Fan Zhang, Dandan Guo, Qing Li, Zhijun Shen, Ruiqing Gao, Chenyu Gao, Zhao Xie, Sentao Fu, Peng Luo, Bufu Tang, Ling Wang   +12 more
wiley   +1 more source

Single‐Cell and Spatial Transcriptomics Uncover Immune Dynamics and Cellular Heterogeneity in Benign Prostatic Hyperplasia and Prostate Cancer Transition

MedComm, Volume 7, Issue 6, June 2026.
Leveraging integrated single‐cell and spatial transcriptomics, we delineated the sustained immunosuppressive landscape during prostate disease progression. Based on this, we have developed a precise gene‐based diagnostic classifier and a multimodal prognostic model.
Yuanyuan Luo, Haitao Zhong, Tongrui Shang, Bin Hu, Dongbo Yuan, Xueyuan Jia, Ruichong Lin, Zehua Wang, Yinyi Fang, Guohua Zhu, Jukun Song, Zhangcheng Liu, Bo Yan, Fa Sun, Zhenyu Jia, Yunfang Yu, Luhui Mao, Hai Huang, Jianguo Zhu   +18 more
wiley   +1 more source

Case Report: Niraparib-abiraterone in HRR-mutated metastatic castration-resistant prostate cancer: clinical insights from five cases. [PDF]

Front Oncol
Vascotto IA, Catalano M, Venturini J, Calandrelli C, Mancini S, Pratesi L, Izzi M, Mela MM, Rossi V, Francini E, Pillozzi S, Antonuzzo L, Roviello G.   +12 more
europepmc   +1 more source

Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview

MedComm, Volume 7, Issue 6, June 2026.
The role of deuterium replacement in drug discovery, its progress, opportunities, and challenges. ABSTRACT Deuterium, the heavy isotope of hydrogen, has unfolded as a cornerstone in modern drug discovery due to its potential to influence metabolic stability and pharmacokinetic behavior.
Mukta Lele, Ajit Manchare, Swapnali Parit, Amol D. Gholap, Krishna Jadhav, Navnath Hatvate, Keshav Raj Paudel, Satish Rojekar   +7 more
wiley   +1 more source

Exploring the pharmacological mechanisms of resibufogenin in castration-resistant prostate cancer via network pharmacology and experimental validation. [PDF]

Front Oncol
Xing Y, Xiang L, Jia Y, Yang Y.
europepmc   +1 more source

Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation

MedComm – Oncology, Volume 5, Issue 2, June 2026.
The abnormal overexpression or gain‐of‐function mutations of EZH2 play a significant role in cancer occurrence and progression, highlighting the importance and potential of EZH2 as a cancer biomarker. Therefore, screening for effective and safe small‐molecule inhibitors, degraders, and natural compounds targeting EZH2 through preclinical cancer models ...
Xi Zhong, Jieni Li, Mingxuan Pan, Xiaoxue Ke, Hongjuan Cui   +4 more
wiley   +1 more source

Phase II Trial of Opaganib Addition in Metastatic Castration-Resistant Prostate Cancer After Disease Progression on Abiraterone or Enzalutamide. [PDF]

Cancer Med
Brown JT, Nazha B, Ferreira AC, Armeson K, Hill EG, Ogretmen B, Mehrotra S, Brisendine A, Magrath G, Plasse TF, Gourdin TS, Kucuk O, Lilly M.   +12 more
europepmc   +1 more source